BYETTA is a non-insulin type 2 diabetes injection medication for adults. Important Safety Information for BYETTA (exenatide) injection . with prior severe hypersensitivity reactions to exenatide or to any of the product components. Byetta 5 micrograms solution for injection in pre-filled pen. Byetta 10 micrograms solution for injection in pre-filled pen exenatide. Read all of this leaflet carefully.
|Published (Last):||24 September 2013|
|PDF File Size:||12.48 Mb|
|ePub File Size:||15.45 Mb|
|Price:||Free* [*Free Regsitration Required]|
Approved Uses BYETTA is an injectable prescription medicine that may improve blood sugar glucose control in adults with type 2 diabetes, when used with diet and exercise.
Go to Healthcare Professional Site. Tell your healthcare provider if you are pregnant or plan to become pregnant. All other trademarks are property of their respective owners. Glucagon-like peptide-1 receptor agonist or bolus insulin with optimized basal insulin in type 2 diabetes. Before taking BYETTA, tell your healthcare provider if you have had pancreatitis, stones in your gallbladder exennatidea history of alcoholism, or high blood triglyceride levels.
Drug Interactions Oral Medications: All other trademarks are property of their respective owners. BYETTA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. The most common insfrt effects with BYETTA include nausea, vomiting, diarrhea, packsge jittery, dizziness, headache, acid stomach, constipation, and weakness.
Use with caution in patients with renal transplantation or when initiating or escalating the dose in patients with moderate renal failure. This product information is intended for US Healthcare Professionals only. Based on animal data, BYETTA packagge cause fetal harm and should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. When used with insulin, evaluate and consider ;ackage the insulin dose in patients at increased risk of hypoglycemia.
Tell your healthcare provider if you have or had kidney problems or a kidney transplant. This site is intended insetr US Consumers. It is unknown whether patients with a history of pancreatitis are at increased risk for pancreatitis while using BYETTA; consider other antidiabetic therapies for these patients.
Pen-sharing poses a risk for transmission of blood-borne pathogens, even if the needle is changed. Because exenatide is commonly associated with gastrointestinal adverse reactions, BYETTA is not recommended in patients with severe gastrointestinal disease eg gastroparesis.
These exenaride be symptoms of pancreatitis. Should not be used in patients with severe renal impairment or end-stage renal disease.
Official BYETTA® (exenatide) injection Healthcare Professional Website
BYETTA is an injectable prescription medicine that may improve blood sugar glucose control in adults with type 2 diabetes, when used with diet and exercise. Not a substitute for insulin and should not be used in patients with type 1 diabetes or diabetic ketoacidosis. Postmarketing reports of serious hypersensitivity reactions eg anaphylaxis and angioedema. Patients may develop antibodies to exenatide. Use with caution with medications that have a narrow therapeutic index or require rapid gastrointestinal absorption.
BYETTA has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, based on postmarketing data. If pancreatitis is suspected, BYETTA should be discontinued promptly and should not be restarted if pancreatitis is confirmed.
Staying Active Learn how regular physical activity can help you manage type 2 diabetes. Your risk for getting low blood sugar hypoglycemia is higher if you take BYETTA with another medicine that can cause low blood sugar, such as a sulfonylurea or insulin. Stop taking BYETTA and call your healthcare provider right away if you have pain in your stomach area abdomen that is severe, and will not go away, occurs with or without vomiting or is felt going from your abdomen through to your back.
Call your healthcare provider right away if you have nausea, vomiting, or diarrhea that will not go away, or if you cannot take liquids by mouth. Oral medications dependent on threshold concentrations for efficacy, such as contraceptives or antibiotics, should be taken at least 1 hour before BYETTA. Postmarketing reports of altered renal function, including increased serum creatinine, renal impairment, worsened chronic renal failure, and acute renal failure, sometimes requiring hemodialysis and kidney transplantation.
If worsening of or failure to achieve exneatide glycemic control occurs, consider alternative antidiabetic therapy. Use of twice-daily exenatide in basal insulin—treated patients with type 2 diabetes: Write your html here You are encouraged to report negative side effects of prescription drugs to the FDA. Go to Patient Site.
To report drug exposure during pregnancy call Postmarketing reports of increased international normalized ratio INR sometimes associated with bleeding with concomitant use of warfarin.
Concurrent use with prandial insulin has not been studied and cannot be recommended. After initiation and dose increases of BYETTA, observe patients carefully for pancreatitis including persistent severe abdominal pain, sometimes radiating to the back, with or without vomiting.
No clinical studies establishing conclusive evidence of macrovascular risk reduction with BYETTA or any other antidiabetic drug.
Add BYETTA to insulin glargine as a complementary action to help improve glycemic control
AstraZeneca provides this link as a service to website visitors. BYETTA should not be used in people with type 1 diabetes or people with diabetic ketoacidosis a condition caused by very high blood sugar.
Talk to your healthcare provider first if you are breastfeeding or plan to breastfeed. The most frequently reported adverse reactions leading to withdrawal for Byetta-treated patients were nausea exenatjde.
The site you are about to visit is maintained by a third party who is solely responsible for its contents.